Summary of Significant Accounting Policies (Details - Restatement) - USD ($) |
3 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|---|---|
Mar. 31, 2022 |
Jun. 30, 2022 |
Sep. 30, 2022 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Dec. 31, 2020 |
|
| New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||||||
| Accounts payable | $ 3,681,900 | $ 1,981,445 | ||||
| Total current liabilities | 4,920,259 | 2,594,188 | ||||
| Total liabilities | 4,920,259 | 2,594,188 | ||||
| Accumulated deficit | (50,715,677) | (35,441,543) | ||||
| Total stockholders' equity | 8,132,856 | 6,163,197 | $ 13,947,984 | |||
| Research and development | 9,300,055 | 9,805,075 | ||||
| Total operating expenses | 15,267,107 | 14,485,915 | ||||
| Loss from operations | (15,267,107) | (14,485,915) | ||||
| Net loss | $ (15,274,134) | $ (14,495,200) | ||||
| Loss per share - diluted | $ (11.22) | $ (16.50) | ||||
| Loss per share - diluted | $ (11.22) | $ (16.50) | ||||
| Cash Flows from Operating Activities: | ||||||
| Accounts payable | $ 1,700,455 | $ 1,035,115 | ||||
| Net cash used in operating activities | $ (10,557,815) | (13,538,309) | ||||
| Previously Reported [Member] | ||||||
| New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||||||
| Accounts payable | $ 489,716 | $ 490,886 | $ 1,005,043 | 1,522,823 | ||
| Total current liabilities | 1,069,300 | 923,856 | 1,244,303 | 2,135,566 | ||
| Total liabilities | 1,069,300 | 923,856 | 1,244,303 | 2,135,566 | ||
| Accumulated deficit | (37,767,260) | (41,333,212) | (44,752,765) | (34,982,921) | ||
| Total stockholders' equity | 14,802,567 | 11,523,456 | 8,393,624 | 6,621,819 | ||
| Research and development | 1,521,364 | 3,742,703 | 5,950,616 | 9,346,453 | ||
| Total operating expenses | 2,781,773 | 6,346,114 | 9,765,129 | 14,027,293 | ||
| Loss from operations | (2,781,773) | (6,346,114) | (9,765,129) | (14,027,293) | ||
| Net loss | $ (2,784,339) | $ (6,350,291) | $ (9,769,844) | $ (14,036,578) | ||
| Loss per share - diluted | $ (2.15) | $ (4.83) | $ (7.40) | $ (15.98) | ||
| Loss per share - diluted | $ (2.15) | $ (4.83) | $ (7.40) | $ (15.98) | ||
| Cash Flows from Operating Activities: | ||||||
| Accounts payable | $ (1,033,107) | $ (1,031,937) | $ (517,780) | $ 576,493 | ||
| Net cash used in operating activities | (3,077,199) | (6,439,733) | (8,252,492) | (13,538,309) | ||
| Revision of Prior Period, Adjustment [Member] | ||||||
| New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||||||
| Accounts payable | 826,061 | 826,061 | 826,061 | 458,622 | ||
| Total current liabilities | 826,061 | 826,061 | 826,061 | 458,622 | ||
| Total liabilities | 826,061 | 826,061 | 826,061 | 458,622 | ||
| Accumulated deficit | (826,061) | (826,061) | (826,061) | (458,622) | ||
| Total stockholders' equity | (826,061) | (826,061) | (826,061) | (458,622) | ||
| Research and development | 367,439 | 367,439 | 367,439 | 458,622 | ||
| Total operating expenses | 367,439 | 367,439 | 367,439 | 458,622 | ||
| Loss from operations | (367,439) | (367,439) | (367,439) | (458,622) | ||
| Net loss | $ (367,439) | $ (367,439) | $ (367,439) | $ (458,622) | ||
| Loss per share - diluted | $ (0.28) | $ (0.28) | $ (0.27) | $ (0.52) | ||
| Loss per share - diluted | $ (0.28) | $ (0.28) | $ (0.27) | $ (0.52) | ||
| Cash Flows from Operating Activities: | ||||||
| Accounts payable | $ 367,439 | $ 367,439 | $ 367,439 | $ 458,622 | ||
| Net cash used in operating activities | 0 | 0 | 0 | 0 | ||
| As Revised [Member] | ||||||
| New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||||||
| Accounts payable | 1,315,777 | 1,316,947 | 1,831,104 | 1,981,445 | ||
| Total current liabilities | 1,895,361 | 1,749,917 | 2,070,364 | 2,594,188 | ||
| Total liabilities | 1,895,361 | 1,749,917 | 2,070,364 | 2,594,188 | ||
| Accumulated deficit | (38,593,321) | (42,159,273) | (45,578,826) | (35,441,543) | ||
| Total stockholders' equity | 13,976,506 | 10,697,395 | 7,567,563 | 6,163,197 | ||
| Research and development | 1,888,803 | 4,110,142 | 6,318,055 | 9,805,075 | ||
| Total operating expenses | 3,149,212 | 6,713,553 | 10,132,568 | 14,485,915 | ||
| Loss from operations | (3,149,212) | (6,713,553) | (10,132,568) | (14,485,915) | ||
| Net loss | $ (3,151,778) | $ (6,717,730) | $ (10,137,283) | $ (14,495,200) | ||
| Loss per share - diluted | $ (2.44) | $ (5.11) | $ (7.67) | $ (16.50) | ||
| Loss per share - diluted | $ (2.44) | $ (5.11) | $ (7.67) | $ (16.50) | ||
| Cash Flows from Operating Activities: | ||||||
| Accounts payable | $ (665,668) | $ (664,498) | $ (150,341) | $ 1,035,115 | ||
| Net cash used in operating activities | $ (3,077,199) | $ (6,439,733) | $ (8,252,492) | $ (13,538,309) | ||
| X | ||||||||||
- Definition Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The cumulative amount of the reporting entity's undistributed earnings or deficit. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|